FLINT, Mich. – April 13, 2015 – JADENU™, recently FDA-approved to treat chronic iron overload, will be available for patients through Diplomat, the nation’s largest independent specialty pharmacy. 

Diplomat Pharmacy, Inc. (NYSE: DPLO) to distribute JADENU™, a drug recently approved by the U.S. Food and Drug Administration to treat patients with chronic iron overload.

Chronic iron overload is a life-threatening toxicity that results from blood transfusions required to treat sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions. Chronic iron overload also can occur in patients with non-transfusion-dependent thalassemia (NTDT) syndromes, due to increased iron absorption in the stomach and intestines. If left untreated, chronic iron overload can damage the liver and heart.

JADENU™ is a new oral formulation of EXJADE® (deferasirox) for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older, and chronic iron due to NTDT in patients age 10 and older. The new drug is the only once-daily oral iron chelator that can be swallowed whole. It can be taken in a single step, with or without a light meal, simplifying daily treatment administration.

“We’re excited to be able to offer patients with chronic iron overload an alternative treatment option through JADENU™,” said Gary Kadlec, Diplomat’s president. “JADENU™ oral tablets make the administration simple and offer an important new option to help meet our patients’ needs.”

JADENU™ is approved under accelerated approval based on a reduction of liver iron concentrations and serum ferritin levels. Please see full prescribing information for JADENU™ at http://www.pharma.us.novartis.com/product/pi/pdf/jadenu.pdf.

To learn more about Diplomat, visit www.diplomat.is.


Forward-Looking Statements 

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include the Company’s expectations regarding future tax benefits, and the financial and operational performance of the combined entities. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: delays or difficulties in integrating the combined businesses; general economic conditions in the regions and industries in which the parties operate; and the ability to achieve cost savings and operating synergies and the timing thereof. The foregoing transaction risks should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.


About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.



Kali Lucas, Marketing & Public Relations
810.768.9580 | press@diplomat.is

Gary Rice, RPH, MS, MBA, CSP, Vice President, Clinical Services
810.768.9863 | grice@diplomat.is